3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
NIH
2
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
265
Leukemia, Lymphocytic, Chronic, B-Cell
66
Lymphoma, Large B-Cell, Diffuse
60
Neoplasms, Plasma Cell
50
Lymphoma, Follicular
45
Lymphoma, Mantle-Cell
42
Lymphoma
41
Recurrence
38
Lymphoma, B-Cell, Marginal Zone
31
Leukemia
30
Leukemia, Myeloid, Acute
27
Lymphoma, B-Cell
19
Lymphoma, Non-Hodgkin
17
Myelodysplastic Syndromes
16
Waldenstrom Macroglobulinemia
15
Smoldering Multiple Myeloma
13
Hodgkin Disease
13
Lymphoma, T-Cell, Peripheral
12
Neoplasms
11
Lymphoma, T-Cell
9
Prostatic Neoplasms
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Lymphoma, T-Cell, Cutaneous
8
Immunoglobulin Light-chain Amyloidosis
8
Burkitt Lymphoma
8
Sezary Syndrome
7
Neoplasm, Residual
7
Mycosis Fungoides
7
Lymphoma, Large-Cell, Anaplastic
7
Leukemia, Plasma Cell
6
Interventions
pembrolizumab
2
fludarabine
2
Radiosurgery
2
Paclitaxel
2
Gemcitabine
2
Cyclophosphamide
2
Cisplatin
2
Carboplatin
2
Anthropogenic Effects
2
venetoclax
1
umbralisib
1
ublituximab
1
regorafenib
1
pazopanib
1
niraparib
1
neratinib
1
lutetium Lu 177 dotatate
1
ibrutinib
1
grapiprant
1
fludarabine phosphate
1
famitinib
1
encorafenib
1
copanlisib
1
cemiplimab
1
capivasertib
1
camrelizumab
1
brigatinib
1
binimetinib
1
axicabtagene ciloleucel
1
avelumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Disease Progression
×
Lenalidomide
×
Clear all
NCT01191060
2026-04-06
IFM/DFCI2009
University Hospital, Toulouse
Phase 3
Completed
700 enrolled